BUSINESS
Pharma weekly wrap: Government to regulate medical devices along the lines of drugs
The government's decision will ensure that medical devices and implants used in India are safe and tested, by bringing all these devices under Indian drug regulator Central Drugs Standard Control Organisation (CDSCO).
BUSINESS
Lupin gets 2 USFDA observations for its Goa plant
Lupin's Goa site, along with Unit 2 manufacturing plant in Pithampur, Indore are under USFDA's warning letter since November 2017.
BUSINESS
Pharma entrepreneur Jayaram Chigurupati death case shifts to Hyderabad police, mystery deepens
According to police, Rakesh Reddy allegedly killed Chigurupati over non-repayment of Rs 5.8 crore loan he had given to the latter.
BUSINESS
Maharashtra to invite tenders worth Rs 2,000 crore for Jyotiba Phule health scheme
Since inception the state government has spent around Rs 5000 crore on premiums and 52 lakh people were benefited.
BUSINESS
Cipla to continue cost cutting via portfolio rationalisation, manufacturing network review
Cipla had exited certain low margin products from the portfolio of its subsidiary Invagen in US.
BUSINESS
Lupin expects better show in Q4FY19 led by US launch of Levothyroxine, Ranolazine
Ranolazine or Renexa used in treatment of chest pain is expected to be launched in Q4 has three months marketing exclusivity. Renexa sold by Gilead Sciences had sales of $758 million.
BUSINESS
The gripping story of pharma entrepreneur Jayaram Chigurupati who lost his fortune, and life
The deal with Ranbaxy made Chigurupati overnight billionaire. Flush with cash he went on to acquire and set up at least a dozen companies.
BUSINESS
The risk of Ayushman Bharat eating into other healthcare schemes looms large
What is worrying is that the allocations for health expenditure remained flat beyond Ayushman Bharat.
BUSINESS
Union Budget 2019 spooks pharma & healthcare cos as govt overlooks their demands
Some of their demands such as bringing down the corporate tax to 25 percent and resumption of 200 percent weighted deduction on R& D were overlooked
BUSINESS
Budget 2019: Spend on PM's pet scheme Ayushman Bharat jumps 167%
Excluding the Ayushman Bharat scheme, increase in health allocation is only 6 percent.
BUSINESS
Justice B N Srikrishna: the go-to man for the government and corporates
Justice Srikrishna shot to fame after his retirement when he headed the "Srikrishna Commission" that investigated the Bombay communal riots of 1992–93.
BUSINESS
Stern action against Chanda Kochhar a warning to India Inc, say corporate governance experts
JN Gupta, Managing Director of Stakeholders Empowerment Services feels the stern action against ICICI Bank's former chief Chanda Kochhar is a warning for other boards of the corporate world.
BUSINESS
Strides to ramp up sales in US, other regulated markets after Australia biz sale
Strides had a net debt of around Rs 1,820 crore as on December 31, 2018.
BUSINESS
Piramal Enterprises says housing loans to be 10% of advances by end-FY19
Loans to real estate developers which constituted about 78 percent in Q2FY19, has come down to 70 percent in Q3.
BUSINESS
Exclusive | Wockhardt confident of business taking off in 3-5 years aided by India, US and antibiotic portfolio launch
After a disastrous 2017-18, there are signs of recovery in FY19. In 9MFY19, sales grew 9 percent and net loss narrowed to Rs 180 crore from Rs 454 crore from last year.
BUSINESS
This week in Pharma: Government sends mixed signals on drug pricing
With elections just a few months away, it seems that the government may not want to side too much with the industry.
BUSINESS
L&T will stick to FY19 guidance, says studying options after SEBI denies buyback
The country's largest infrastructure company had earlier said that it was expecting a 12-15 percent increase in revenue and 10-12 percent increase in order inflows in the current fiscal.
BUSINESS
Biocon Q3 net profit zooms over twofold to Rs 217.2 cr
Revenues from the biologics vertical, that comprises biosimilars, rose 136 percent to Rs 449 crore driven by the biosimilar Pegfilgrastim gaining market share in the US.
BUSINESS
Lupin's specialty drug Solosec gains traction in US on rising prescriptions
Lupin expects the drug to hit peak sales of $100-$150mn over next 3-4 years, making it a big contributor.
BUSINESS
Allegations on Sun Pharma may tighten scrutiny on related party distribution model in sector
Sun Pharma’s domestic formulation business is entirely routed through a promoter-owned entity called AML, a super stockist that was declared as a related party of the company only during FY18.
BUSINESS
Drug pricing regime: Pharma companies express relief, health activists miffed
Indian pharmaceutical industry was rattled by the decision of former NPPA chairman Bhupendra Singh, who used special powers conferred under Paragraph 19 of the Drug Price Control Order (DPCO) 2013, to slash prices of hundreds of drug formulations, which were not part of National List of Essential Medicines (NLEM).
BUSINESS
Sun Pharma takes steps to limit damage, discontinues AML and unwinds loans
In a filing to stock exchanges on January 22, the company said its distribution related to its domestic formulations business shall be transitioned from AML, the current distributor, to a wholly owned subsidiary of Sun Pharma
BUSINESS
Sun Pharma may discontinue Aditya Medisales super stockist arrangement
Sun Pharma’s domestic formulation business is entirely routed through a promoter-owned entity called AML, a super stockist that was declared as related party of the company only during FY18.
BUSINESS
Weekly blog: Sun Pharma’s governance woes may not fade away soon
The latest whistle-blower complaint alleges large transactions between Aditya Medisales (AML) and Suraksha Realty, controlled by Sun Pharma’s co-promoter Sudhir Valia, out of the money generated from the publicly-listed company
